The Pill Penalty: A Four-Year Subsidy Written Into a Price Control

In the United States, a small-molecule drug becomes eligible for Medicare price negotiation seven years after approval. A biologic becomes eligible eleven years after licensure. Because a negotiated maximum fair price takes effect two years after selection, the effective protected commercial life works out at nine years for a pill and thirteen for an injectable.

Four years. That is not a patent term, not an exclusivity period and not a regulatory incentive — it is the arithmetic of a price-control statute, and it is the single most consequential fact in biopharmaceutical capital allocation today. The Congressional Research Service’s own summary of the Inflation Reduction Act’s negotiation programme sets out the mechanism without editorialising: a chemical drug must have been approved for at least seven years and must have no marketed generic substitute; a biological product must have been licensed for at least eleven years and must have no marketed biosimilar substitute. Ten drugs are negotiated for prices effective in 2026, fifteen more for each of 2027 and 2028, and twenty in each year from 2029.

The ceiling on the negotiated price carries a second duration effect. It is the lesser of the drug’s weighted average net price or a percentage of the non-federal average manufacturer price — 75 per cent for a product approved for fewer than sixteen years, 40 per cent for one approved sixteen years or more. Duration is priced twice: once in when you are selected, and again in how much you can be cut.

The approval counts do not match the revenue story

The FDA’s 2025 novel approvals, published in its annual new drug therapy review, went 34 new molecular entities and 12 therapeutic biologics out of 46 — 26.1 per cent biologic by count. Including CBER, there were 58 novel approvals. Those counts are broadly stable against a historical average of 38 novel drugs a year since 2007.

So on volume, the pill is not dying. What is dying is the pill’s annuity. A 26 per cent share of approvals can support a much larger share of industry value if each biologic earns for thirteen protected years and each pill for nine — and that is precisely what the capital markets have been pricing.

The biosimilar record makes the same point from the other direction. The FDA approved 18 biosimilars in 2025, four of them for reference products that had no biosimilar before. Since 2015 it has approved 81 biosimilars across 20 reference products — an average of 4.05 approvals per molecule. That is not the structure of a generic wave; it is a stack. Competition arrives all at once on a handful of molecules and then stops, because the next molecule is not yet legally copyable. A biosimilar entrant therefore faces an oligopoly that becomes a price war which ends when the marginal entrant decides the volume is not worth the plant.

The realistic reading of a 10 per cent market

Pheonix Research’s forecast for biotechnology runs from USD 1.58 trillion in 2025 to USD 3.42 trillion in 2033 at a stated 10.15 per cent; the endpoints compound at 10.13 per cent, so the headline is sound. Medical biotechnology is the largest segment and genomic and cell therapy is the fastest growing.

That 10.15 per cent is almost entirely price and mix, not volume. Approval counts are flat to slightly up. Growth of that order on flat unit counts means the average approved product is getting more expensive and staying protected for longer — which is exactly what a statute that pays for duration would produce.

It also tells you where the constraint sits. If value accrues to long-duration injectables, then the scarce asset is not the chemistry. It is validated manufacturing capacity, the kind that can be audited, scaled and qualified on a schedule. That is the reason contract development and manufacturing organisations occupy a strategic position they did not hold fifteen years ago, and the reason tariffs applied to imported biologics are a margin event rather than an existential one: a molecule that requires a qualified facility cannot be re-sourced the way a consumer good can.

Three things this thesis does not claim

First, it is a US fiscal mechanism. European purchasing works through reference pricing, external price referencing and health technology assessment, none of which pays a premium for a longer protected life in the way Medicare’s negotiation calendar does. The capital allocation effect is therefore strongest for portfolios oriented to US Part D and Part B revenue, and weakest for those built on European tender volume.

Second, a long exclusivity period is not the same as a valuable product. Thirteen years of protection on a molecule that fails to differentiate in a crowded class produces thirteen years of discounting. Duration protects price; it does not create demand.

Third, the mechanism is amendable. A four-year wedge of this size invites repeal, delay or redesign in any subsequent budget cycle, and a portfolio built on it carries political risk that does not show up in a patent cliff chart.

What it does claim is narrower and harder to argue with. When a price-control statute applies one clock to pills and another to injectables, the industry’s research budget responds. The pipeline mix that shows up in 2032 was decided by the calendar that was written in 2022.